Menu
Your Cart

Viral RNA/DNA Isolation Automation System

Viral RNA/DNA Isolation Automation System
For fast extraction and purification of nucleic acids from various kinds of biological samples, in 96 well format.High quality: Equal or better results compared with other brands. Lower cost: Guaranteed 30% - 50% less cost than other brands. Faster: One button start; Run time is ..
$48,000.00
For fast extraction and purification of viral nucleic acids from various kinds of biological samples collected in multiple transport media.  Novel and original magnetic nanoparticle technology for nucleic acids isolation.  Various sample types: swabs, saliva, blood.  Optimized standar..
$14,500.00
For fast extraction and purification of viral nucleic acids from various kinds of biological samples collected in multiple transport media.  Novel and original magnetic nanoparticle technology for nucleic acids isolation.  Various sample types: swabs, saliva, blood.  Optimized standar..
$3,725.00
For fast extraction and purification of viral nucleic acids from various kinds of biological samples collected in multiple transport media.  Novel and original magnetic nanoparticle technology for nucleic acids isolation.  Various sample types: swabs, saliva, blood.  Optimized standar..
$843.75
Fifty deep well plates, 96 well each.  Case of 50 deep well plates.   Cat # A901214.Documentation:Product brochure: Apostle-COVID-19-Viral-RNA-Isolation-System.pdfSystem protocol: Apostle-MiniGenomics-Viral-Total-NA-Isolation-MagTouch-protocol.pdfApplication Note: ..
$424.60
Fifty tip combs, 96 well eachCase of 50 tip combsCat # A901212Documentation:Product brochure: Apostle-COVID-19-Viral-RNA-Isolation-System.pdfSystem protocol: Apostle-MiniGenomics-Viral-Total-NA-Isolation-MagTouch-protocol.pdfApplication Note: Application-Note-Apostle-Viral-RNA-Is..
$397.80
Showing 1 to 6 of 6 (1 Pages)
Nature Communications just published a clinical study, including 2125 cancer patients, 9 cancer types, using the Apostle Minimax cfDNA technology. This study demonstrates the ability of its model to detect early-stage cancers using cfDNA, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection. Congratulations to this clinical research team. To date, the Apostle Minimax cfDNA technology has been used in 2 articles published in Nature Medicine, 1 in Nature Communications, 1 in Science Translational Medicine, 1 in PNAS, and over 50 scientific articles in different journals.